Bionomics Limited
https://www.bionomics.com.au/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Bionomics Limited
Bionomics Posts Positive Data In PTSD With Struggling Anxiety Drug
After failing in a Phase II trial in social anxiety disorder, Bionomics thinks mid-stage data for BNC210 in post-traumatic stress disorder may now position the drug as a novel therapy for PTSD.
Vistagen Getting 'Back On Offense’ After US FDA Okays Endpoint For Its Social Anxiety Drug
CEO Shawn Singh discusses path forward for fasedienol (PH94B) using the classic LSAS primary endpoint in next clinical trial. Pherine nasal spray candidate failed to meet the primary endpoint (the patient-reported SUDS) in its first pivotal Phase III study, whose design was constrained by the Covid pandemic.
VistaGen Staggered By Latest Clinical Setback, This Time In Social Anxiety
Failure of pherine nasal spray candidate in first of two Phase III trials for social anxiety disorder puts program in doubt, while the California biotech’s share price craters.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- Eclipse Therapeutics, Inc., Iliad Chemicals Pty Limited
- Bionomics, Inc.
- Prestwick Chemical
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice